September 23, 2014 5:08 PM ET

Pharmaceuticals

Company Overview of Relypsa, Inc.

Company Overview

Relypsa, Inc., a pharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States. The company’s principal product candidate includes Patiromer, a non-absorbed potassium binder that completed Phase 3 clinical trial for the treatment of hyperkalemia. It also offers RLY6002, a pre-clinical product candidate that evaluates as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus. The company was founded in 2007 and is headquartered in Redwood City, California.

700 Saginaw Drive

Redwood City, CA 94063

United States

Founded in 2007

84 Employees

Phone:

650-421-9500

Key Executives for Relypsa, Inc.

Chief Executive Officer
Age: 49
Total Annual Compensation: $287.3K
Founder
Total Annual Compensation: $172.5K
Chief Medical Officer and Senior Vice President
Age: 43
Total Annual Compensation: $321.9K
Senior Vice President of Pharmaceutical Development & Regulatory Affairs
Age: 61
Total Annual Compensation: $304.0K
Senior Vice President of Pharmaceutical Operations
Age: 55
Total Annual Compensation: $292.0K
Compensation as of Fiscal Year 2013.

Relypsa, Inc. Key Developments

Relypsa Reports Manufacturing Agreement for Blood Drug

Relypsa announced a multi-year agreement with Patheon, Inc. to manufacture of patiromer, RLYP's hyperkalemia drug. Hyperkalemia refers to elevated levels of potassium in the blood, often resulting from chronic kidney disease, hypertension, diabetes and/or heart failure. Hyperkalemia can lead to life-threatening cardiac arrhythmia and sudden death.

Relypsa, Inc. Announces Data from its Pivotal Phase 3 Clinical Trial of Patiromer

Relypsa, Inc. announced that data from its pivotal Phase 3 clinical trial of patiromer will be presented as a late-breaking oral presentation at the 18(th) Annual Scientific Meeting for the Heart Failure Society of America (HFSA) to be held in Las Vegas during September 14-17, 2014. The data will be presented at HFSA by Bertram Pitt, M.D., professor of Medicine, Emeritus, University of Michigan School of Medicine. An analysis of the data will be presented that assesses the ability of patiromer to reduce elevated serum potassium (serum K(+)). Following the achievement of normal potassium levels, the study then evaluated whether continued treatment with patiromer would maintain control of serum K(+) and reduce the recurrence of hyperkalemia compared to placebo. The analysis was conducted in heart failure (HF) patients with chronic kidney disease (CKD) and mild to severe hyperkalemia who were also receiving renin angiotensin aldosterone system (RAAS) inhibitor therapy. In addition to presenting placebo-controlled comparative data on the recurrence of hyperkalemia after having controlled serum potassium levels, the presentation will include findings on whether HF patients in the study were able to remain on guideline-recommended RAAS inhibitor therapy.

Relypsa, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revised Financial Guidance for the Full Year 2014

Relypsa, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations was $16,397,000, net loss of $16,737,000 or $0.51 per basic and diluted share against loss from operations was $16,283,000, net loss of $20,220,000 or $64.87 per basic and diluted share a year ago. For the six months, the company reported loss from operations was $32,101,000, net loss of $32,805,000 or $1.04 per basic and diluted share against loss from operations was $41,422,000, net loss of $46,471,000 or $149.42 per basic and diluted share a year ago. With respect to financial expectations for the full year 2014, the company is narrowing its operating expense guidance to a range of $75.0 to $85.0 million, including $5.0 to $10.0 million in stock-based compensation, from a range of $75.0 to $95.0 million. The 2014 operating expenses will be primarily driven by ongoing development activities and expansion of commercial launch preparation activities related to patiromer and increases in the company's general and administrative infrastructure.

Similar Private Companies By Industry

Company Name Region
Damage Control Technologies, Inc. United States
PharmaNutrients, Inc. United States
Rapidscan Pharma Solutions, Inc. United States
Digestive Care, Inc. United States
INSMED Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
May 30, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Relypsa, Inc., please visit www.relypsa.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.